Nayacure Labs

Nayacure Labs is a regenerative medicine company developing technologies to restore the function of failing body parts and enhance human health. Nayacure is building a pipeline of therapeutic assets and product candidates to address a range of diseases: artificial clot for localized drug delivery (based on the natural ability of drugs to bind to plasma proteins), organs on demand, and a placental stem cell therapy for neurodegeneration. Nayacure's lead program is in developing personalized organs in an effort to make more organs available for transplantation and substantially reduce the need for immunosuppressant drugs following organ transplantation. Nayacure's goal is to cross the immunological barrier to xenotransplantation, providing an unlimited source of humanized organs and treating human-derived composite allografts (e.g. extremities, face, and womb) to reduce their immunogenic burden and make them tolerable.

Nayacure Labs was founded in 2010 by Shahar Cohen, MD (Founder & CEO).

Nayacure Labs operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Nayacure Labs is based in Orvani St 9, Zikhron Ya'akov, Israel, Center District.